MELBOURNE, AUSTRALIA--(Marketwire - July 17, 2008) - Prana Biotechnology Limited (NASDAQ: PRAN) (ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, today announced that Dr. Jeffrey Cummings, the Chairman of Prana’s Research and Development Advisory Board has been invited to present findings from the company’s Phase IIa clinical trial during the “Hot Topics” session at the 2008 International Conference on Alzheimer’s Disease (ICAD) to be held in Chicago, Illinois. Dr. Cummings will be presenting a talk entitled “Targeting Abeta as a Modifying Therapy of Alzheimer’s Disease: Safety, Efficacy and Biomarker Findings of a Phase IIa Randomised, Double-Blind Placebo-Controlled trial of PBT2" on July 30 at 11:15am.
